Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025 - Summary - MDSpire
Advertisement
Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025
To update consensus statements on the management of locally advanced and metastatic renal cell carcinoma (RCC) based on recent evidence and expert panel discussions, highlighting the importance of adapting to evolving treatment paradigms.
Key Findings:
42 consensus statements were accepted, reflecting updated treatment strategies and practices.
Adjuvant therapy for locally advanced RCC is now recommended based on recent evidence.
Immunotherapy-based combination therapy is emphasized for various types of metastatic RCC, enhancing treatment options.
Active surveillance is suggested for mRCC patients with very favorable prognosis, providing a tailored approach.
Belzutifan is recognized as a novel therapeutic agent for metastatic RCC, expanding the therapeutic landscape.
Interpretation:
The updated consensus statements provide a contemporary framework for managing locally advanced and metastatic RCC, significantly impacting clinical practice and patient outcomes.
Limitations:
Research gaps remain in the management of RCC, particularly in long-term outcomes and patient selection.
The consensus is primarily based on expert opinion and recent literature, which may evolve as new evidence emerges.
Conclusion:
These guidelines serve as practical references for clinicians in Hong Kong and the Asia-Pacific region, aiming to improve patient outcomes in RCC management.
by Darren M. C. Poon, Philip W. K. Kwong, Samson Y. S. Chan, Brian S. H. Ho, Martin H. C. Lam, K. S. Law, Angus K. C. Leung, Clarence L. H. Leung, David K. W. Leung, W. K. Ma, Barry B. W. Wo, Kenneth C. W. Wong, Philip Y. Wu, Peter K. F. Chiu
